Startup Funding

Menu
Subscribe
Search
The Growth Story Framework: What Top VCs Look for in Follow-On Rounds

The Growth Story Framework: What Top VCs Look for in Follow-On Rounds

•
Fundraising, Investing

Related Guides

    Trending

    The most popular articles on Startup Funding in the past day.

    How to Diligence a Cleantech Firm

    December 7, 2025

    7 min read How to Diligence a Cleantech Firm Diligence for a cleantech firm requires a different lens than for traditional software, CPG, or marketplace investing. Whether you’re an angel investor, family office, strategic, or VC, evaluating a cleantech business means examining technology readiness, regulatory compliance, unit economics, carbon impact, capital intensity, and infrastructure dependencies. Here’s a structured, risk-aware playbook to diligence a cleantech company with confidence. 1. Understand the Business Model & Unit Economics   a. Revenue Model & Cost Structure Determine whether the company generates revenue through hardware sales, SaaS layers, project development, installation contracts, or long-term service agreements (e.g., O&M or energy-as-a-service). Break down COGS: components, engineering labor, installation, freight, commissioning, and warranty obligations. Ask how margins improve with volume: Are hardware components commoditized or proprietary? Do economies of scale significantly reduce manufacturing costs? Are service contracts profitable over their lifecycle? b. Lifetime Value (LTV) & Customer Acquisition Costs (CAC) For enterprise or municipal customers: What is the expected contract term? How often do customers expand deployments? What is the churn for service agreements? For residential solutions (e.g., solar installers, battery providers): Evaluate gross profit per project. Compare customer lifetime profit to CAC and installation labor costs. c. Pricing Strategy How price-sensitive is the market? Does the company compete on cost savings, performance, or sustainability ROI? How do market incentives (tax credits, grants, utility rebates) affect pricing? Ensure the pricing model remains viable even if subsidies decrease or competition intensifies. 2. Technology Readiness & Scalability Risks   a. Technology Validation (TRL Levels) Assess technology readiness: Has it been lab-validated, pilot-tested, or commercially deployed? Request: Independent validation reports Performance data Warranty or reliability metrics Identify any unproven assumptions that could hinder commercialization. b. Manufacturing & Supply Chain Where and how is the product manufactured? In-house, outsourced, or contract manufacturing? Are critical components single-source (e.g., rare earth metals, lithium cells)? Evaluate supply-chain resiliency: Lead times Supplier diversification Exposure to geopolitical risk c. Scalability Constraints Does scaling require: Large capex investment? Specialized labor? Utility interconnection approval? Local permitting or environmental assessments? Assess whether physical constraints—not just demand—could limit growth. 3. Market & Go-to-Market Strategy   a. Target Market & Adoption Curve Who are the customers—utilities, industrials, municipalities, real estate developers, corporates, or consumers? Analyze: Market size Market fragmentation Regulatory tailwinds (e.g., IRA incentives, net metering policy) Determine if the market is ready for the solution or if customer education will slow sales cycles. b. Sales Model & Distribution Is the company using direct sales, channel partners, installers, EPCs, or distributors? For enterprise or government sales: Review sales cycle length Contract structure RFP dependency Proof of traction with anchor customers c. Customer Proof & Brand Positioning Evaluate customer testimonials, commercial pilots, and measurable outcomes (e.g., kWh reduction, CO₂ saved, O&M savings). Assess whether the company’s differentiation—performance, sustainability, cost savings, or reliability—is real and defensible. 4. Regulatory, Policy & Compliance Considerations   a. Certifications & Safety Request certification documents such as: UL, CE, ISO standards Grid interconnection compliance (e.g., IEEE standards) Environmental or emissions certifications Check whether the product has undergone third-party testing. b. Policy Dependencies Many cleantech firms depend on incentives. Understand: How the business performs with and without subsidies Risks from policy changes Exposure to tariffs, import duties, or trade restrictions c. Permitting, Interconnection & Local Regulations For grid-dependent products: Interconnection timelines Utility approval processes Permitting risks For environmental tech: EPA, state-level environmental regulation Potential liabilities (e.g., waste handling, emissions compliance) 5. Product & Innovation Pipeline   a. Product-Market Fit Review pilot results, customer feedback, reliability metrics, uptime rates, and warranty claims. Evaluate whether early adopters are becoming long-term customers, and whether the product delivers measurable ROI. b. R&D Roadmap Ask for: Pipeline of next-gen technology Development timelines Budget allocation between R&D and commercialization Intellectual property strategy (patents, trade secrets) Request evidence of technical milestones, not just conceptual roadmaps. c. Competitive Moats Assess whether the company’s innovation is defensible through: Patents Proprietary materials or algorithms Exclusive supply agreements Data advantages High switching costs 6. Team & Operational Execution   a. Founding Team & Technical Expertise Do founders have expertise in energy, engineering, sustainability, hardware, or manufacturing? Have they brought physical technology to market before? b. Organizational Strength Examine structure across engineering, operations, sales, installation, and regulatory functions. Evaluate whether the company has: Solid program/project management Scalable operational processes Strong supply chain and field operations teams c. Execution Metrics Request KPIs such as: Deployment timelines Installation costs Uptime and reliability metrics Warranty claim rates On-time delivery and backlog status Look for signs of operational discipline like documented SOPs and audited processes. 7. Financials & Capital Structure   a. Historical Financials Request: 2–3 years of financial statements Cash flow breakdown (critical for capex-heavy firms) Gross margin trends Equipment and installation cost data Assess whether the company’s growth justifies its burn rate. b. Financial Model & Scenarios Review projections with a focus on: Unit economics under scale Sensitivity to commodity prices Capex requirements for growth Working capital needs (especially for hardware) Installation labor availability Model downside cases: What if incentives drop, cost of materials rises, or deployment slows? c. Cap Table & Funding Requirements Request a detailed cap table including SAFEs, notes, and options. Understand: Existing investor rights Liquidity preferences Future capital needs and dilution risk Dependency on project financing or credit facilities 8. Customer Validation & Market Risk   a. Customer References Speak with customers in pilot or commercial deployments. Ask: Did the technology meet expectations? Was the installation smooth? Did it generate real cost or carbon savings? Would they expand usage? b. Competitive Landscape Map direct and indirect competitors: Incumbents Emerging cleantech startups Cross-category substitutes (e.g., batteries vs. thermal storage) Assess defensibility and switching costs. c. Infrastructure & Channel Risk Evaluate dependencies such as: Utility approval cycles Installation labor availability Supply chain bottlenecks Dependence on one large customer or geographic region 9. ESG, Sustainability & Risk Management   a. Environmental Impact Request lifecycle analyses or carbon footprint data. Verify claims around emissions reduction, recyclability, and energy savings. b. Resilience &

    How to Diligence a Therapeutic Startup

    November 15, 2025

    7 min reading How to Diligence a Therapeutic Startup “In therapeutic investing, the science must be right, but the strategy must be smarter.” Diligencing a therapeutic startup is unlike any other form of early-stage investing. It requires balancing scientific rigor with business realism. From molecule to market, investors must evaluate not just whether the science works, but also whether the pathway to revenue and, eventually, to exit is both capital-efficient and strategically defensible. In this article, we distill insights from Startup Funding Espresso episodes on diligence, biotech assessment, and founder fit to create a structured playbook for investors, founders, and diligence teams navigating therapeutic innovation. The Purpose of Diligence Therapeutic startups operate at the intersection of science, regulation, and capital markets. The goal of diligence is to validate alignment across three domains: Technical feasibility — Does the underlying science or technology platform hold up under scrutiny? Regulatory viability — Is there a clear pathway through the FDA, EMA, or equivalent agencies? Commercial potential — Is the market large enough, accessible enough, and ready enough to support sustained adoption? The episode “Setting up Due Diligence” underscores that diligence is not a checklist but a risk-reduction process. Each layer, technical, market, financial, and team, reveals not only what’s known but also where uncertainty resides. Key Pillars of Therapeutic Diligence Across episodes like “What Investors Look for in a Biotech Startup”, “Core Skills for Biotech Drug Development”, and “Best Practices for Therapeutic Startup Fundraising,” five diligence pillars consistently emerge: a. Scientific Validity Evaluate the mechanism of action and supporting pre-clinical data. Look for peer-reviewed validation or collaborations with credible institutions. Avoid overreliance on early, non-replicated studies. b. Regulatory Readiness Determine if the company understands its regulatory classification (drug, biologic, device, or combination product). The episode “Key Documents for Your Due Diligence Box” reminds investors to confirm the presence of pre-IND or pre-submission feedback and a mapped timeline to key milestones (IND, Phase I/II/III, etc.). c. Intellectual Property Strong IP defines competitive durability. Diligence teams should verify patent ownership, freedom-to-operate analyses, and upcoming expirations. The episode “Red Flags in Due Diligence” lists weak patent coverage and licensing ambiguity as common deal-killers. d. Market and Reimbursement The episode “How to Diligence the Market” highlights the importance of mapping addressable markets, reimbursement codes, and pricing elasticity early. In therapeutics, the buyer is often not the user; understanding payer dynamics is as critical as clinical efficacy. e. Team and Execution From “How to Diligence the Team” and “How Much Diligence to Run on a Founder,” we learn that successful therapeutic founders combine scientific depth with regulatory and commercial literacy. Look for balanced teams, scientific founders complemented by business operators and regulatory veterans. Evaluating the Science: From Discovery to Translation Scientific diligence is both art and analytics. The episodes “Technical Due Diligence” and “Performing Due Diligence Like a VC” emphasize reviewing: Preclinical data integrity (sample sizes, control design, statistical significance). Translational relevance (animal model to human trial correlation). Scalability of the therapeutic platform (manufacturing, formulation, delivery). Replicability and documentation quality. The diligence process should involve external subject-matter experts who can assess biological plausibility and experimental design. Investors often underestimate how manufacturing complexity and stability testing can become multi-million-dollar bottlenecks post-Series A. Regulatory Diligence: Navigating the FDA Maze Episodes like “Due Diligence: The Thorough Approach” and “Signing NDAs in Due Diligence” note that regulatory diligence is not just about confidentiality; it’s about clarity. Investors should verify: Has the company engaged with the FDA through pre-IND or Q-submission meetings? Does the clinical plan align with regulatory precedent? Are timelines and budgets realistic given the required studies? For devices and diagnostics, the 510(k), De Novo, and PMA pathways drastically change time-to-market and capital requirements. For drugs, investors should validate the clinical endpoints that regulators will recognize and the CMC (Chemistry, Manufacturing & Controls) readiness. Market Validation and Adoption Risk The episodes “How to Perform Marketing Due Diligence” and “The Role of Social Media in Due Diligence” remind us that even brilliant therapies fail if they can’t cross the commercial chasm. Critical diligence questions include: Who pays for this therapy—patients, insurers, or hospitals? What’s the comparative cost versus the current standard of care? How do KOLs (Key Opinion Leaders) view the therapeutic value? Savvy investors go beyond market sizing they look for evidence of early traction, like investigator interest, LOIs from clinics, or grants validating unmet needs. Financial and Risk Diligence In “Financials, Team and Domain Diligence” and “Going Through Due Diligence,” Hall T. Martin highlights the need to align scientific milestones with capital tranches. Key insights include: Link fundraising to de-risking events (e.g., IND submission, Phase I completion). Assess capital efficiency: how much per data point? Model downside scenarios: what happens if the lead candidate fails? Therapeutic startups should demonstrate clear cash-to-value conversion, showing how each dollar accelerates the next stage of validation. Qualitative and Quantitative Diligence From “The Quantitative and Qualitative Side of Due Diligence,” effective investors integrate metrics and intuition. Quantitatively, they evaluate market size, runway, and clinical timelines. Qualitatively, they examine founder motivation, transparency, and resilience. The best diligence blends data with discernment; a founder’s honesty in disclosing failed experiments often signals stronger integrity than perfect slides. Common Red Flags Episodes like “Red Flags in Due Diligence” and “What Isn’t Being Said in Due Diligence” reveal recurring warning signs: Overstated preclinical results or missing negative data. Lack of clarity on IP ownership or licensing. Unrealistic regulatory timelines. Founders are resistant to third-party validation. Weak capitalization structure or unrecorded convertible debt. Any one of these can indicate a lack of maturity in governance or readiness for institutional investment. Building the Due Diligence Box The “Key Documents for Your Due Diligence Box” episode lists must-have files: Executive summary and pitch deck Scientific white papers IP portfolio summary Regulatory correspondence Financial model and cap table Team bios and advisory board profiles For therapeutics, include clinical protocol summaries and manufacturing validation reports. Organizing these early signals professionalism and preparedness. Performing Diligence Like a VC In “Performing Due Diligence Like a VC,” the guidance

    How to Diligence a Marketplace Startup

    November 9, 2025

    10 min read How to Diligence a Marketplace Startup The Hidden Complexity of Marketplace Investing Marketplace startups look deceptively simple—connect buyers and sellers, take a transaction fee, and scale. Yet beneath the surface lies one of the most intricate business models in venture capital. Each marketplace comprises three intertwined systems: supply acquisition, demand generation, and transaction trust. Diligencing such a company requires investors to look beyond vanity metrics and into the structural mechanics that sustain the network. Unlike SaaS or product companies, a marketplace’s moat emerges not from technology alone but from network density, unit economics, and behavioral liquidity. Accurate diligence measures how these forces interact over time—not just whether the platform is growing, but whether it is compounding. 1. Market Definition and Network Dynamics Total Addressable Market (TAM) and Fragmentation Start with clarity on the target market’s size and fragmentation. The best marketplaces often enter highly fragmented, inefficient markets where incumbents lack digital coordination, such as real estate agents, local services, or niche B2B verticals. A large TAM alone isn’t enough; investors should assess whether participants are ready for platformization. Markets with strong offline incumbents or regulatory friction may resist the shift. Ideal markets have: Many small, independent providers have poor discovery tools. High-frequency transactions that encourage repeat use. A clear “pain point” in finding, vetting, or paying counterparties. Two-Sided Liquidity: Solving the Cold Start Problem The cold-start problem — how to attract both sides of the market simultaneously — is the defining risk for early marketplace ventures. During diligence, look for tactical liquidity strategies: Single-vertical focus: Does the company start narrow to seed density before expanding? Demand priming: Are they subsidizing one side (often the supply side) until cross-traffic builds? Community seeding: Is there an existing user base or offline network that can be digitized quickly? Early liquidity in even a small segment signals the flywheel potential that investors prize. 2. Business Model and Unit Economics Revenue Model Fit The most common monetization models include take rates (transaction fees), subscription tiers, and lead-generation fees. Each implies different risk structures. Transaction fees require trust, and an integrated payment is high-value but high-friction. Subscription models indicate recurring revenue but can mask low transaction activity. Lead models work early but limit scalability once competition rises. Investors should ask: Is the monetization aligned with the core user value? A mismatch between value creation and value capture, like charging suppliers before buyers exist, can choke early growth. Economics per Transaction Healthy marketplaces exhibit a positive contribution margin once acquisition costs normalize. During diligence, evaluate: Take rate vs. CAC: Does the average customer transaction justify the acquisition cost? Repeat usage: Is retention improving as users deepen engagement? Cohort profitability: Do earlier cohorts improve over time (a sign of compounding trust)? An investor-grade model includes LTV/CAC ratios above 3x, declining CAC, and evidence that organic or referral traffic is growing faster than paid channels. 3. Supply and Demand Validation Supply-Side Diligence Strong supply is the backbone of marketplace liquidity. Look for evidence of supply stickiness: Contracts, integrations, or switching costs that prevent churn. Platform tools that embed suppliers’ inventory management, CRM, and analytics. Precise segmentation of high-value vs. low-value suppliers. Investors should scrutinize how supply quality is maintained at scale. The best marketplaces curate, not just aggregate through reputation systems, ratings, or algorithmic filtering. Demand-Side Diligence Demand validation is equally critical. Look for signals of habitual usage: Percentage of users completing transactions vs. browsing. Repeat rate within 30–90 days. Conversion from search to transaction. If acquisition is primarily through paid channels, ask whether organic channels (SEO, referrals, word of mouth) are growing. A healthy marketplace eventually “earns” its traffic through brand trust and liquidity, not just ad spend. 4. Trust, Safety, and Transaction Infrastructure Trust is the invisible currency of marketplaces. Investors often underestimate the importance of dispute resolution, escrow systems, and user verification. Diligence questions to ask: How does the platform mitigate fraud or low-quality interactions? Is there buyer and seller verification? How quickly are disputes resolved? What share of GMV occurs on-platform versus off-platform? A marketplace with a strong safety reputation accelerates network effects. Each satisfied user adds both volume and confidence to future participants. 5. Technology, Data, and Defensibility Technology as an Enabler, Not the Moat While marketplaces are technology-enabled, their defensibility lies more in data loops than in code. Assess: Proprietary matching algorithms or dynamic pricing systems. Unique datasets built from repeated transactions. Predictive analytics is improving the balance between supply and demand. Technology amplifies the moat once scale is achieved, but rarely substitutes for it. Diligence should confirm that technology shortens the distance between intent and transaction. Network Effects and Switching Costs Ask: Do more users make the platform better for all participants? Are switching costs increasing (data lock-in, reputation scores, embedded tools)? Is there evidence of local network effects, city-by-city or niche-by-niche density? True network effects are measurable: declining CAC, improving retention, and rising transaction frequency as density grows. 6. Regulatory and Operational Risks Marketplaces often enter semi-regulated sectors (transportation, healthcare, finance). Investigate compliance exposure early: Licensing or labor classification risks (e.g., gig economy). Data privacy or payment compliance (PCI, GDPR). Local versus national jurisdiction variance. Operational diligence should review internal controls—how the company handles disputes, refunds, and payment reconciliation. Hidden liabilities here can erode margins later. 7. Team, Culture, and Execution Capability In marketplaces, execution discipline matters as much as vision. Founders must balance product growth with operational rigor. Red flags include: Overemphasis on growth without tracking unit economics. Weak analytical culture or reliance on anecdotal success stories. Lack of expertise in supply-chain or logistics for physical marketplaces. Green flags include: Founders who deeply understand both sides of the market. Clear frameworks for scaling liquidity (e.g., city rollout models). Experienced data and operations leadership. Diligence should include references and operator interviews with those who have scaled networks before, as they are rare and invaluable. 8. Investor Fit and Exit Pathways Investors must map the marketplace’s growth to their own fund model. Marketplaces can deliver large exits but often require long gestation periods before compounding effects take hold. Key investor diligence checkpoints: Time to liquidity: Are transaction volumes doubling

    How to Diligence a Deeptech Startup

    November 9, 2025

    5 min read How to Diligence a Deeptech Startup Deeptech investing sits at the frontier of science and innovation where research, engineering, and commercialization intersect. Unlike pure software startups, deeptech ventures build defensible advantages through hard science: novel materials, AI hardware, quantum systems, robotics, medtech, or energy storage breakthroughs. These opportunities are exciting but also carry unique risks. Traditional venture diligence frameworks often fall short when technology readiness, regulatory hurdles, and manufacturing scalability dominate the risk stack. This article distills key lessons from Startup Funding Espresso episodes on diligence, technology risk, and commercialization. The goal: to help investors and founders apply a structured, evidence-based approach to evaluating deeptech startups. Why Deeptech Diligence Is Different Every deeptech company compresses three risk domains—science, engineering, and market adoption into a single domain. The challenge is not just whether the technology works, but whether it can be built repeatedly, validated independently, and sold at scale. Traditional diligence focuses on traction and market fit; deeptech diligence begins earlier, with proof-of-concept data, IP defensibility, and regulatory feasibility. Investors must verify not only what exists today but also how quickly risk can be reduced per dollar invested. Key mindset shifts include: From forecasting revenue to mapping technology readiness. From tracking KPIs to testing falsifiable hypotheses. From scaling growth to scaling evidence. 1. Technology and IP — The Foundation of Value The first diligence lens is technical validation. Investors must separate scientific promise from engineering reality. Ask: What has been independently demonstrated, and what remains unproven? Use a Technology Readiness Level (TRL) framework to map progress: TRL 3–5: Lab validation and prototype proof-of-concepts. TRL 6–7: Pilot or limited field trials with defined performance metrics. TRL 8–9: Qualified production systems ready for deployment. Request replicable data, third-party lab results, prototype test reports, and failure analyses. Look for structured experimentation and defined “next proof milestones.” Equally critical is IP defensibility. Strong patent portfolios are not measured by quantity but by claim strength, enforceability, and market coverage. Review patent claims with a freedom-to-operate (FTO) analysis and assess continuation plans. Green flags: independent validation, multiple claims granted, clear continuation strategy.Red flags: single provisional filings, overlapping prior art, or reliance on unprotected trade secrets. 2. Regulatory and Standards Pathway Many deeptech sectors—especially medtech, energy, and advanced materials face heavy regulatory oversight. Evaluate: Applicable standards and certifications (FDA, CE, UL, ISO, ITAR, etc.). Defined testing phases, costs, and lead times. How compliance and certification are budgeted within the funding round. A credible startup presents stage-gated plans, design verification, safety testing, and third-party audits with clear contingency budgets. Failing to anticipate certification hurdles can derail commercialization even when performance is strong. 3. Manufacturing and Supply Chain Deeptech ventures live or die by manufacturing scalability. A prototype in a lab is far from a product on a production line. Focus diligence on: Design for Manufacturability: Has the team engineered around tolerances, yield loss, and cost variability? Supplier validation: Are key materials single-sourced or dual-qualified? Cost curves: Does the company model BOM reduction as a function of volume? Unit economics should improve with scale—not degrade under real-world conditions. Review supplier references, pilot production data, and yield reports, along with contingency plans for critical components. 4. Market Validation and Go-to-Market Strategy Deeptech adoption is slower and more conservative. Market traction is measured by pilots, paid proofs of concept (POCs), and letters of intent (LOIs), not user downloads. Ask: Who are the anchor customers? Are there signed pilots with success metrics? Do successful pilots convert to purchase orders or rollout commitments? Look for evidence of market pull rather than push. Strong startups identify a beachhead market, a narrow, high-value initial use case to expand from once technical and regulatory risks are reduced. 5. Business Model and Unit Economics Deeptech success depends on translating innovation into a sustainable business. Assess: Pricing logic: value-based or cost-plus. Service model: warranty, maintenance, support obligations. Margin progression: gross margin by production lot and expected BOM reductions. Validate a clear path to profitability once production stabilizes. Many deeptech companies underestimate hidden costs tooling, certification renewals, and warranty exposure. Confirm how gross margins evolve with scale and how service costs are managed. 6. Team and Execution Capability Winning deeptech teams blend: Scientific depth (core technology and IP creation). Engineering discipline (system integration, QA, and reliability). Commercial skill (enterprise sales and regulatory navigation). Assess whether the team balances technical and operational expertise, or knows when to bring in external expertise. Signs of execution maturity: Detailed experiment and pilot schedules. Hiring plans tied to risk milestones. Advisors or board members with relevant domain expertise. The best teams demonstrate self-awareness and a plan to close capability gaps as they grow. 7. Financial and Capital Planning In deeptech, capital efficiency equals risk reduction per dollar spent. Each round should connect the capital directly to the risk milestones: Proof of principle → validated prototype. Prototype → regulatory clearance or pilot. Pilot → scaled production or recurring revenue. Ensure the round fully funds the next de-risking event. Partial funding during critical phases, such as certification, can dramatically increase failure risk. Common Red Flags Reliance on anecdotal or non-replicable data. Undefined or unrealistic regulatory timelines. Missing supplier validation for long-lead components. Pilots without success criteria or written commitments. IP limited to provisional filings without FTO analysis. When several appear together, they signal structural risks, not minor gaps. Clear Green Flags Independent third-party validation of test data. Detailed regulatory roadmap with time and budget estimates. Qualified manufacturing partners and early yield data. Paid pilot contracts with expansion pathways. Documented BOM and cost-reduction roadmap. These signals indicate a company transitioning from research to execution, where investors can confidently participate in scaling innovation. Read More from TEN Capital Education here.

    Challenges in Angel Investing

    January 28, 2024

    1 min read Investing Challenges in Angel Investing. Angel investing can be fun and financially rewarding to the investor as well as helpful to the startup. It can also be challenging. Before considering becoming an angel investor, there are some challenges to consider: It’s Hands-On Angel investing requires hands-on work with the startups in funding and supporting them after the investment. Angels often fill in the gaps left by the local incubators and accelerator programs by coaching them into a place where they can raise funding. First-time angels can find it time-consuming and expensive to learn the process. It Requires Continuing Education New market segments require the angel investor to learn new industries and business models continually. It’s Risky There’s no collateral for the investment, and it can all go to zero as it’s a risky investment class. One out of ten investments will be a home run, two or three will provide a small return on investment, and the rest will fail. But it Can be Worth it Angel investing is not without its challenges, but it can truly be a rewarding endeavor. Read More from TEN Capital Education here. Hall T. Martin is the founder and CEO of the TEN Capital Network. TEN Capital has been connecting startups with investors for over ten years. You can connect with Hall about fundraising, business growth, and emerging technologies via LinkedIn. Are you currently raising funding? Contact us today about how we can help! https://tencapital.group/contact-us/

    Challenges in Angel Investing

    January 28, 2024

    1 min read Investing Challenges in Angel Investing. Angel investing can be fun and financially rewarding to the investor as well as helpful to the startup. It can also be challenging. Before considering becoming an angel investor, there are some challenges to consider: It’s Hands-On Angel investing requires hands-on work with the startups in funding and supporting them after the investment. Angels often fill in the gaps left by the local incubators and accelerator programs by coaching them into a place where they can raise funding. First-time angels can find it time-consuming and expensive to learn the process. It Requires Continuing Education New market segments require the angel investor to learn new industries and business models continually. It’s Risky There’s no collateral for the investment, and it can all go to zero as it’s a risky investment class. One out of ten investments will be a home run, two or three will provide a small return on investment, and the rest will fail. But it Can be Worth it Angel investing is not without its challenges, but it can truly be a rewarding endeavor. Read More from TEN Capital Education here. Hall T. Martin is the founder and CEO of the TEN Capital Network. TEN Capital has been connecting startups with investors for over ten years. You can connect with Hall about fundraising, business growth, and emerging technologies via LinkedIn. Are you currently raising funding? Contact us today about how we can help! https://tencapital.group/contact-us/

    How to Invest in Startups- Learn From Other Investors

    January 22, 2024

    1 min read How to Invest in Startups – Learn From Other Investors  As an investor, I helped launch three angel networks in Texas. In the process, I set up training programs, attended conferences, and talked with many other investors. Hearing and speaking to other investors was a wonderful learning tool. One of the best resources I found was a podcast by Frank Peters. Frank was an angel investor out of the Tech Coast Angels in southern California. The Frank Peters Show Frank interviewed every angel, VC, and startup in the southern California community. He later ran interviews across the US and all over the world. He ultimately recorded over 450 episodes, which he posted on the web. As I drove my car, I listened to many podcasts and heard from angel investors about how they invested in their investment thesis and the lessons they learned from the process. I recommend listening to podcasts that focus on startup funding. Podcasts are an excellent tool to learn from experts in the field. Some of my favorites are Jason Calacanis’s Angel Podcast, Patrick O’Shaughnessy’s Invest Like the Best, and there is also my personal podcast, Investor Connect.  Read More from TEN Capital Education here. Hall T. Martin is the founder and CEO of the TEN Capital Network. TEN Capital has been connecting startups with investors for over ten years. You can connect with Hall about fundraising, business growth, and emerging technologies via LinkedIn. Are you currently raising funding? Contact us today about how we can help! https://tencapital.group/contact-us/

    What Investors Look For

    October 5, 2023

    2 min read What Investors Look For So you’re about to raise funding for your startup and wonder what investors look for. Startups can be pretty shy about discussing their current revenue in the business’s early stages. Being pre-revenue or just beginning to show traction is typical in the beginning, and investors know this. Even if you are pre-revenue, you can show traction with your startup. You define your traction as customer activity, and you don’t need to have revenue to show there’s traction with customers. To exhibit that you have traction while pre-revenue, focus on customer engagement at all phases, even before you have a product. One of the most important things to understand as an early-stage startup is this: The investor doesn’t care about the size of the revenue. What investors look for is the predictability of that revenue. If you do have a sales funnel, it’s helpful to share that with the investors. Having visibility on that progress is vital because the investor can then see the traction you have in your sales prospecting process. Use the funnel in multiple investor updates to show how prospects are moving through it. When speaking with investors, mention your process with phrases such as: “For every ten leads, we generate one customer worth $5000 in revenue.” Showing leads is precisely what investors are looking for. It shows that you have a system with repeatable and predictable outcomes. Additionally, when communicating with investors, always include the customers in your discussions. Never engage in an investor meeting without new information about your customers and always mention any updates you have on revenue. TEN Capital helps startups, growth companies, and investors, raise funding through its extensive network of accredited investors. Our Funding as a Service program includes investor introductions, an email campaign with updates, pitch events, webinars, podcast interviews, and assistance with investment closing documents including pitch decks and data rooms. In short: we provide the leg-work, saving you time and money. Read More TEN Capital Education Here Hall T. Martin is the founder and CEO of the TEN Capital Network. TEN Capital has been connecting startups with investors for over ten years. You can connect with Hall about fundraising, business growth, and emerging technologies via LinkedIn or email: hallmartin@tencapital.group

    The Many Startup Investor Types and Who is Right for Your Deal?

    September 4, 2023

    2 min read The Many Startup Investor Types and Who is Right for Your Deal? There are many kinds of startup investors today. Venture Capital, MicroVC Funds, Corporate Venture funds, Family Offices,  Angels, High Net Worth Individuals (HNI), and crowdfunders to name some of the current types of investors. Venture Capital- Most startups think of venture capital when they start their fundraise. The reality is that venture capital is only for a small number of startups. VCs draw their funds from outside sources called LPs or Limited Partners. The VC charges a management fee and a carry (share of the profits) from the funds raised. There are VCs who still raise the funds in what is called committed capital- the funds are committed by the LPs. Newer VC funds are often called “Pledge funds” in which the LPs pay the management fee for access to the deal flow but they review each deal before funding and have a say in the funding process. For some VCs you may notice the turnaround time on questions and deal flow takes longer. For pledge funds, the VCs must gain the approval of the LPs to move forward- hence the turnaround time is longer. VCs fund only the top 10% of all qualified startups. They look for high-growth, large target markets with scalable business models. MicroVCs are venture capital funds with less than $100M in funding. Typically, MicroVCs start with $25M to $50M funds and then deploy the funds to 10-12 companies. They often have very specific investment criteria since the management fee on the fund doesn’t add up to much and one needs to keep the costs low on such a fund. Corporate VCs are often called strategic investors in that they invest for strategic reasons rather than financial ones. They seek new technologies, talent, and other tools to help grow their business. They often invest as follow-on investors and typically do not lead the fundraise for startups. Some firms had a strategic fund in the past, but today just about every company has a fund for startup investment. Family offices are investors based around a family partnership that allocates some of their funds to startup investing. Some family offices go it alone and are called single-family offices while others band together into groups and are called multi-family offices that share the deal flow and due diligence. For every venture capital fund in the US, there are five family offices. They are less prominent since they invest privately and provide very little publicity around their work. Angels are individuals that meet the SEC-accredited investor requirement. That means they have $1M in net worth not counting the house they live in. Angels invest their own money. Some band together into groups to share the deal flow and the due diligence. Sometimes the group is formed around the “dinner club” model and a formal application process is used to recruit the deals. Others form syndicates in which a deal that is led is shopped to others in the group. The dinner club model can be a heavy time sync since most of the meetings are in person and only occur at specific times of the year. The Syndicate model is lighter and focuses on deals that have a lead. Angels look for the same thing as VCs but often invest outside those parameters since it’s their own funds.  They often invest in something that matters to them personally such as impact funds. High Net Worth Individuals are similar to angels but typically have more investing experience. They most often invest their own funds in areas they understand well. Some HNIs band together in informal syndicates to share the deal flow and due diligence. Crowdfunders are either accredited or unaccredited investors seeking to make a return by investing with many other investors in startup deals. Because their investment size ranges from $100 to $5000 in most cases, the startup needs a large number of them to complete a round. Crowdfunders more than any other investor make their investment decision on factors other than financial return. They often invest to support family and friends, or businesses they care about in some manner.  Read More TEN Capital Education Here Hall T. Martin is the founder and CEO of the TEN Capital Network. TEN Capital has been connecting startups with investors for over ten years. You can connect with Hall about fundraising, business growth, and emerging technologies via LinkedIn or email: hallmartin@tencapital.group

    Site Map

    Scroll to Top